Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

378.21

Mkt cap

88B

Volume

1.9M

High

387.70

P/E Ratio

13.88

52-wk high

567.26

Low

375.29

Div yield

0.02

52-wk low

375.29

Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) for potential breaches of fiduciary duties by its officers and directors. The investigation aims to determine if securities laws were violated, impacting shareholders.

Portfolio Pulse from

December 12, 2024 | 4:00 am

Elevance Health has demonstrated strong financial performance with a 9.1% revenue CAGR and 13.7% EPS growth over the past decade. Despite recent share price weakness, its long-term fundamentals remain strong, presenting an investment opportunity. The stock is attractively valued with a forward PE of 11.2x, lower than its 10-year average, and potential upside from AI integration.

Portfolio Pulse from

December 11, 2024 | 4:00 pm

Elevance Health's stock fell after its subsidiary, Anthem Blue Cross Blue Shield, faced backlash over a new anesthesia policy. The company has since reversed the policy change.

Portfolio Pulse from

December 06, 2024 | 6:00 pm

Johnson Fistel, LLP is investigating Elevance Health, Inc. for potential securities law violations related to misrepresentation or failure to disclose material information, which may have led to investor losses.

Portfolio Pulse from

December 04, 2024 | 6:30 pm

Elevance Health (ELV) has seen a 20% decline in its stock price over the past three months due to challenges like higher benefit costs, increased debt, and member attrition in its Medicaid business. These issues are causing investor concerns.

Portfolio Pulse from

November 12, 2024 | 7:15 pm

Johnson Fistel, LLP is investigating Elevance Health, Inc. for potential securities law violations related to misrepresentation or failure to disclose adverse information, which may have led to investor losses.

Portfolio Pulse from

November 07, 2024 | 10:00 pm

Elevance Health (NYSE:ELV) has outperformed the market over the past 15 years with an average annual return of 15.1%, surpassing the market by 2.99% annually. A $100 investment in ELV 15 years ago would now be worth $850.24.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 8:06 pm

Morgan Stanley has maintained an Overweight rating on Elevance Health but has lowered the price target from $643 to $551.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:02 pm

Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health but lowers the price target from $622 to $501.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 4:22 pm

Analysts have provided mixed evaluations for Elevance Health (NYSE:ELV) over the past quarter, with a trend towards lowering price targets. The average 12-month price target is now $559.91, down 7.03% from the previous $602.27. Despite some positive financial metrics, such as ROE and ROA, Elevance Health faces challenges with net margin and revenue growth compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 8:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.